

# Gastrointestinal (GI) Disease-Oriented Team

---

Clinical Research Treatment Trial Flowchart



### NEOADJUVANT

**A022104/Janus Trial**  
(Triplet vs. double chemo)

Coord: A. Luna  
PI: Dr. Zell  
Accrual: 4/15

**CCTG-CO32**  
(NEO-RT trial)

Coord: P. Yang  
PI: Dr. Zell

Accrual: 0/5

**EA2201**  
(Nivo + Ipi + radiation)

Coord: K. Ghio  
PI: Dr. Valerin  
Accrual: 0/3

**UCI 21-67**  
(Epcadostat + short course  
radiation + chemo)

PI: Dr. Valerin  
Pending activation

### ADJUVANT

**NRG-GI008/CIRCULATE**  
(ctDNA guided tx)

Coord: A. Luna  
PI: Dr. Zell  
Accrual: 1/5

### INTRA-OPERATIVE

**UCI 20-163**  
(SOC vs CG-100 Intraluminal)

Coord: M. Nguyen  
PI: Dr. Carmichael  
Accrual: 2/10  
Bypass Device

### MOLECULAR FAILURE

**UCI 20-43**  
(TAS102 + irinotecan)

Coord: K. Ghio  
PI: Dr. Dayyani  
Accrual: 5/11



### 1L METASTATIC

**UCI 22-07**  
 (BXQ-350 + mFOLFOX7  
 and bevacizumab)

Coord: N. Ferrand  
 PI: Dr. FC Lee  
 Accrual: 5/8

**A022101**  
 (at least 4 months of  
chemo once metastatic  
 disease is confirmed)

Coord: A. Luna  
 PI: Dr. Eng  
 Accrual: 0/2

### 2L METASTATIC

**S2107**  
 (Encorafenib + cetuximab +/- nivo)

Coord: LM Aguilar

PI: Dr. Valerin  
 Accrual: 2/3

**UCI 21-208**  
(currently closed for all CRC cohorts)  
 (Anti-DR5 targeting pentameric Igm antibody IGM-8444)

Coord: M. Nguyen

PI: Dr. Chow  
 Accrual: 9/15

**UCI 21-39**  
 (Pembro + TATE)

Coord: LM Aguilar  
 PI: Dr. Abi-Jaoudeh  
 Accrual: 19/30



Newly Diagnosed

ECOG-EA2182  
(Mitomycin-C + 5-Fluorouracil +  
Capecitabine)  
  
Coord: J. Koff  
PI: Dr. Zell  
Accrual: 1/3

Advanced/Metastatic

ECOG-EA2176  
(Nivolumab + Carboplatin +  
Paclitaxel)  
  
Coord: J. Koff  
PI: Dr. Valerin  
Accrual: 4/5

## Neoadjuvant

### UCI 21-191

(SOC therapy with ctDNA testing)

Coord: A. Luna  
PI: Dr. Dayyani  
Pending activation

## Newly Diagnosed Metastatic

### UCI 20-87

(V Paclitaxel + IV 5-FU + IV leucovorin + IP paclitaxel)

Coord: LM Aguilar  
PI: Dr. Senthil  
Accrual: 23/30

### UCI 21-193

(FGFR inhibitor + mFOLFOX6 + antiPD-L1 (nivolumab))

Coord: J. Koff  
PI: Dr. Dayyani  
Accrual: 1/12

### A022102

(mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab)

Coord: J. Koff  
PI: Dr. Dayyani  
Accrual: 4/7

### UCI 21-10

(FOLFOX + nivo + Bispecific antibody (anti-CLDN18.2 + anti-4-1BB))

Coord: K. Ghio/J. Koff  
PI: Dr. Dayyani  
Accrual: 12/17

### EA2183

(SOC + XRT)

Coord: J. Koff  
PI: Dr. Seyedin  
Accrual: 0/7

## Recurrent

### UCI 23-78

(EGFR and MET-directed antibody)

Coord: J. Koff  
PI: Dr. Dayyani  
Accrual: 0/3

### UCI 16-94

(Tirapazamine, Nivolumab)

Coord: LM Aguilar  
PI: Dr. Abi-Jaoudeh  
Accrual: 26/40

### UCI 23-109

(Disitamab Vedotin + Tucatinib)  
**(opened 4/25/24)**

Coord: M. Nguyen  
PI: Dr. Dayyani  
Accrual: 1/10

### UCI 22-51

**(opened 3/7/24)**  
(ASP2138)

Coord: N. Ferrand  
PI: Dr. Dayyani  
Accrual: 2/10

### UCI 23-200


(AZD0901)

Coord: TBD  
PI: Dr. Dayyani  
Pending activation

### UCI 24-49

(Beamion BCGC-1: Oral Zongertinib + Trastuzumab Deruxtecan or + Trastuzumab Emtansine)

Coord: TBD  
PI: Dr. Dayyani  
Pending activation





# Advanced Solid Tumor

**UCI 23-85**  
(BA3182 +  
(EPCAM)/CD3  
Antibody)  
  
Coord: TBD  
  
PI: Dr. Valerin  
Pending activation

**UCI 21-146**  
(Anti-Tissue Factor  
monoclonal  
antibody-  
BCNvcMMAE  
conjugate)  
  
Coord: C. Kang  
PI: Dr. Dayyani  
Accrual: 5/11

**ETCTN-10579**  
(ZEN003694 (ZEN-  
3694) +  
capecitabine)  
  
Coord: P. Yang  
  
Accrual: 0/4

**UCI 22-37**  
(Inhibitor of KDM4  
histone  
demethylase)  
  
Coord: A. Luna  
PI: Dr. Dayyani  
Accrual: 5/10

**UCI 22-26**  
(Androgen and  
glucocorticoid  
receptor  
antagonist)  
  
Coord: N. Ferrand  
  
PI: Dr. Dayyani  
Accrual: 7/12

**UCI 22-221**  
BiTe of B7-H6  
  
(Central B7-H6 testing)  
HCC and Pancreatic  
(also NSCLC, HNSCC,  
CRC, and gastric)  
  
Coord: P. Yang  
PI: Dr. Dayyani  
Accrual: 3/12



**UCI 03-03**

(Immunologic response analysis)

Coord: B. Sanchez  
PI: Dr. Imagawa  
Accrual: 262/400

**UCI 20-101**

(Biospecimen Collection for patients planned to start treatment)

Coord: N. Arechiga  
PI: Dr. Senthil  
Accrual: 53/80

**UCI 23-21**

(Exosome Gene Expression Peritoneal Fluid & Plasma in Gastrointestinal Malignancies)

Coord: LM Aguilar  
PI: Dr. Senthil  
Accrual: 0/70

**UCI 20-04**

(Tissue Collection)

Coord: B. Sanchez  
PI: Dr. Dayyani  
Accrual: 98/130

**UCI 22-109**

(alonosteron buccal film vs. IV Palonosetron)

Coord: P. Yang  
PI: Dr. Dayyani  
Accrual: 1/30